LP
TAK icon

LMR Partners’s Takeda Pharmaceutical TAK Stock Holding History

LMR Partners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-85,766
Closed -$1.26M – 1725
2025
Q3 		$1.26M Buy
85,766
+51,166
+148% +$760K 0.01% 865
2025
Q2 		$535K Sell
34,600
-78,795
-69% -$1.16M ﹤0.01% 928
2025
Q1 		$1.69M Sell
113,395
-116,605
-51% -$1.63M 0.02% 688
2024
Q4 		$3.05M Buy
+230,000
New +$3.16M 0.03% 500
2024
Q2 		– Sell
-271,143
Closed -$3.77M – 1312
2024
Q1 		$3.77M Buy
271,143
+178,128
+192% +$2.59M 0.04% 405
2023
Q4 		$1.33M Sell
93,015
-368,089
-80% -$5.22M 0.02% 532
2023
Q3 		$7.13M Buy
461,104
+362,114
+366% +$5.61M 0.08% 217
2023
Q2 		$1.56M Buy
+98,990
New +$1.62M 0.02% 387
2023
Q1 		– Sell
-151,409
Closed -$2.37M – 1161
2022
Q4 		$2.37M Sell
151,409
-437,205
-74% -$6.11M 0.04% 473
2022
Q3 		$7.66M Buy
+588,614
New +$8.18M 0.14% 183
2022
Q1 		– Sell
-507,814
Closed -$6.92M – 1351
2021
Q4 		$6.92M Buy
507,814
+191,800
+61% +$2.69M 0.07% 204
2021
Q3 		$5.25M Sell
316,014
-517,442
-62% -$8.69M 0.06% 247
2021
Q2 		$13.9M Buy
833,456
+657,812
+375% +$11.2M 0.21% 92
2021
Q1 		$3.2M Buy
+175,644
New +$3.16M 0.08% 227
2020
Q4 		– Sell
-2,446,614
Closed -$43.4M – 624
2020
Q3 		$43.4M Sell
2,446,614
-904,528
-27% -$16.5M 0.89% 13
2020
Q2 		$59.7M Sell
3,351,142
-92,843
-3% -$1.67M 1.49% 9
2020
Q1 		$53.4M Buy
3,443,985
+1,727,583
+101% +$31.3M 2.49% 8
2019
Q4 		$34.2K Sell
1,716,402
-820,482
-32% -$15.7M 0.06% 43
2019
Q3 		$43.3M Sell
2,536,884
-2,026,707
-44% -$35.1M 2.14% 11
2019
Q2 		$80.9M Buy
4,563,591
+3,171,256
+228% +$57.7M 2.95% 7
2019
Q1 		$28.4M Buy
+1,392,335
New +$28M 1.45% 16

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LMR Partners's TAK Position: Q4 2025 in Review

LMR Partners sold out of Takeda Pharmaceutical (TAK) in Q4 2025, closing a stake of 85,766 shares — an estimated $1.26M sold.

LMR Partners first reported a position in TAK in Q1 2019 and held it in 21 quarters. The position peaked at $80.9M in Q2 2019. 348 funds tracked by Wall St. Rank hold TAK as of Q4 2025.

  • LMR Partners reported no remaining Takeda Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • LMR Partners sold 85,766 Takeda Pharmaceutical shares in Q4 2025, an estimated $1.26M.
  • LMR Partners first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 21 quarters.
  • LMR Partners's Takeda Pharmaceutical position peaked at $80.9M in Q2 2019.
  • 348 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2025.

Based on LMR Partners's 13F filing for Q4 2025, filed 17 Feb 2026.